Young Blood May Hold the Weapons for Targeting Age-Related Diseases
October 15, 2019
(Chemical & Engineering News) – In the wake of the initial fervor surrounding young blood, researchers are taking a more measured approach. Rather than trying to reverse aging, they’re identifying the molecular factors responsible for the changes seen in parabiosis experiments in hopes of targeting specific diseases associated with aging, such as age-related macular degeneration or Alzheimer’s disease. “Right now, conducting a clinical trial for aging is extremely difficult,” says Eric Verdin, CEO of the Buck Institute for Research on Aging. A targeted approach could yield practical treatments more quickly and with fewer ethical and other concerns than simply transfusing patients with young blood, researchers say.